EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment with cathepsin L inhibitor potentiates Th2-type immune response in Leishmania major-infected BALB/c mice



Treatment with cathepsin L inhibitor potentiates Th2-type immune response in Leishmania major-infected BALB/c mice



International Immunology 13(8): 975-982



Prior to the activation of CD4 (+) T cells, exogenous proteins must be digested by endo/lysosomal enzymes in antigen-presenting cells (APC) to produce antigenic peptides that are able to be presented on class II molecules of the MHC. Studies described here inspect the functional significance of cathepsin L inhibition for antigen processing and T (h) 1/T (h) 2 differentiation in experimental leishmaniasis. We first demonstrated using in vitro systems that cathepsin L is one of the candidate endo/lysosomal enzymes in processing of soluble Leishmania antigen (SLA) and that its specific inhibitor, CLIK148, modulated the processing of SLA. BALB/c mice are known to be susceptible to infection with Leishmania major. Interestingly, treatment of BALB/c mice with CLIK148 exacerbated the infection by enhancing the development of SLA-specific T (h) 2-type response such as production of IL-4 and generation of T (h) 2-dependent specific IgE/IgG1 antibodies. Moreover, addition of CLIK148 in incubation of a SLA-specific CD4 (+) T cell line with APC up-regulated the production of IL-4. However, CLIK148 did not exert any direct influence on the function of T cells themselves. Taken together, these findings suggest that treatment of host mice with CLIK148 affects the processing of SLA in APC, resulting in the potentiation of T (h) 2-type immune responses and thus leading to exacerbation of the infection. Furthermore, endo/lysosomal cathepsin L was found to be functionally distinct from previously described cathepsins B and D.

(PDF emailed within 0-6 h: $19.90)

Accession: 003993331

Download citation: RISBibTeXText

PMID: 11470767

DOI: 10.1093/intimm/13.8.975



Related references

Cathepsin B-inhibitor promotes the development of Th1 type protective T cells in mice infected with Leishmania major. Journal of Medical Investigation 44(1-2): 33-39, 1997

The influence of the site of parasite inoculation on the development of Th1 and Th2 type immune responses in (BALB/c x C57BL/6) F1 mice infected with Leishmania major. Parasite Immunology 17(11): 569-579, 1995

Co-infection with Toxoplasma gondii switches the expected TH2 immune response into TH1, limiting inflammation and tissue parasitism in BALB/C mice infected with Leishmania major. Memorias do Instituto Oswaldo Cruz 93(SUPPL 2): 223-224, 1998

Indomethacin treatment slows disease progression and enhances a Th1 response in susceptible BALB/c mice infected with Leishmania major. Parasite Immunology 21(5): 273-277, 1999

In vitro indomethacin administration upregulates interleukin-12 production and polarizes the immune response towards a Th1 type in susceptible BALB/c mice infected with Leishmania mexicana. Parasite Immunology 23(11): 599-606, 2001

Modulation of the immune response of Balb/c mice against Leishmania major by imuvert. International Journal of Immunopharmacology 19(8): 443-449, 1997

Cathepsin L is crucial for a Th1-type immune response during Leishmania major infection. Microbes and Infection 6(5): 468-474, 2004

Regulatory B cells shape the development of Th2 immune responses in BALB/c mice infected with Leishmania major through IL-10 production. Journal of Immunology 184(2): 886-894, 2010

Priming of a beta-galactosidase (beta-GAL)-specific type 1 response in BALB/c mice infected with beta-GAL-transfected Leishmania major. Infection and Immunity 68(2): 809-814, 2000

Th2 responses in Leishmania major-infected wild-type and interleukin-4-deficient BALB/c mice. Immunology 92(SUPPL 1): 39, 1997